Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T22:17:49.398Z.
Calculation as of: 2026-10-06T22:17:49.398Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f4a2befa970cab8c9956b6d8c2bddfeceb0bcb8bde8cbc5a5c0f5a0c0e258424
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Monopar Therapeutics Inc.
Market Cap
$533.04M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$531.98M
Price/OCF Ratio
27.16
TTM Avg
30.64
3Y Avg
39.07
5Y Avg
39.07
Market Cap
$548.51M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$516.76M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Monopar Therapeutics Inc. (MNPR) | $533.04M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 27.16 | 30.64 | 39.07 | 39.07 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | N/A | N/A | N/A | N/A |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | N/A | N/A | N/A | N/A |
| ProKidney Corp. (PROK)vs › | $538.01M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $519.25M | N/A | 0.26 | 0.26 | 0.26 |
| Phathom Pharmaceuticals, Inc. (PHAT)vs › | $548.51M | N/A | N/A | N/A | N/A |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $557.32M | N/A | 41.16 | 40.24 | 16.59 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
